Related Experiment Videos
Serum prostate-specific antigen levels in stage A1 prostatic cancer
American Journal of Clinical Pathology
|August 1, 1993
Summary
Serum prostate-specific antigen (PSA) testing may not detect early-stage prostate cancer (CAP). Most stage A1 CAP patients had normal PSA levels, suggesting elevated PSA indicates a larger tumor burden.
Area of Science:
- Urology
- Oncology
- Biochemistry
Background:
- Serum prostate-specific antigen (PSA) is widely used, but its role in prostate cancer (CAP) screening is debated.
- Concerns exist about detecting indolent CAP foci that may not impact patient outcomes.
Purpose of the Study:
- To evaluate serum PSA levels in patients diagnosed with stage A1 CAP.
- To determine if PSA levels can effectively identify early-stage prostate cancer.
Main Methods:
- Retrospective analysis of 143 men undergoing transurethral resection for presumed benign prostatic hyperplasia.
- Serum PSA levels were measured within 8 weeks of surgery.
- Patients were categorized based on pathological findings: no cancer, stage A1 CAP, or advanced CAP.
Main Results:
- 11 of 143 patients (7.7%) had stage A1 CAP; 8 (5.6%) had advanced CAP.
- The mean PSA level for stage A1 CAP was 2.3 ng/mL, lower than the 3.8 ng/mL mean in the benign group.
- 10 of 11 stage A1 CAP patients had PSA levels below 4.0 ng/mL.
Conclusions:
- Most patients with stage A1 CAP do not exhibit elevated serum PSA levels.
- Elevated PSA levels in the context of CAP may indicate a tumor burden exceeding that of stage A1 disease.
- Current PSA screening thresholds may miss early-stage prostate cancer.